Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, shows a favorable pharmacokinetic and safety profile across multiple phase 1 studies.
Saved in:
| Title: | Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, shows a favorable pharmacokinetic and safety profile across multiple phase 1 studies. |
|---|---|
| Authors: | Feldmüller M; Clinical Pharmacology, Research and Development, Pharmaceuticals, Bayer AG, Berlin, Germany., Jodl SJ; Translational Medicine, Research and Development, Pharmaceuticals, Bayer AG, Berlin, Germany., Ploeger B; Model-Informed Drug Development, Research and Development, Pharmaceuticals, Bayer AG, Berlin, Germany., Wagenfeld A; Translational Science, Pharmaceuticals, Bayer AG, Berlin, Germany., Wiesinger H; Clinical Pharmacology, Research and Development, Pharmaceuticals, Bayer AG, Berlin, Germany., Zollmann FS; Pharma Consult, Berlin, Germany., Klein S; Research and Early Development Statistics, Research and Development, Pharmaceuticals, Bayer AG, Berlin, Germany., Zhang R; Medical Affairs China, Pharmaceuticals, Bayer Healthcare Co., Ltd., Beijing, China., Rohde B; Translational Medicine, Research and Development, Pharmaceuticals, Bayer AG, Berlin, Germany., Höchel J; Early Clinical Development, Research and Development, Pharmaceuticals, Bayer AG, Berlin, Germany. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2025 May 30; Vol. 16, pp. 1521505. Date of Electronic Publication: 2025 May 30 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
